top of page


Eli Lilly partners with Hims & Hers to expand access to Zepbound and Foundayo obesity medicines
Lilly's commercial partnership with Hims & Hers brings two FDA-approved obesity treatments into an integrated telehealth prescribing and delivery pathway, with published self-pay starting prices from $149 per month.

nuaxia
Nov 92 min read


Lilly’s Oral GLP-1 Foundayo Wins FDA Approval, Intensifying Obesity Drug Market Competition
New oral weight-loss treatment enters the market as competition with Novo Nordisk’s oral Wegovy accelerates.

nuaxia
Apr 21 min read
bottom of page